Has Daniel Mannas, MD received payments from drug or device companies?

Yes. Drug and device makers reported $1,426 in general payments to Daniel Mannas, MD across 13 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Daniel Mannas, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Daniel Mannas, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Daniel Mannas, MD

Urology · Farmington, NMNPI 1811287782

Payments from drug & device makers

What this record shows

This record is dominated by travel and lodging: $940 of the $1,426 with a category attached, or 65.9%. Neotract Inc. accounts for 84.7% of it on its own, with 4 other manufacturers making up the rest. Reporting peaked in 2019 at $1,207 and has fallen 88.5% since, to $139 in 2024. That places this record below the midpoint for urology clinicians in NM, where the typical reported total is $1,519.

$1,426in general payments, 2019–2025

Across 13 payments — averaging $109.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Neotract Inc.$1K
Pfizer$90
KARL Storz Endoscopy-america$83
Philips North America LLC$31
Boston Scientific$14

What the payments were for

Travel & lodging$94066%
Food & beverage$41629%
Education$705%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Neotract Inc.	3	$1,207
Pfizer	5	$90
KARL Storz Endoscopy-america	2	$83
Philips North America LLC	2	$31
Boston Scientific	1	$14

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

UroLift$1,207

How this compares

$1,426 in reported general payments places this provider in the 45th percentile of 46 urology providers in New Mexico.

See all urology providers in New Mexico →

Medicare billing

Part B allowed, 2024

$244,238

Medicare patients

620

Services billed

7,260

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
MyrbetriqMirabegron	110	$79,977
Tamsulosin Hcl	589	$12,414
PremarinEstrogens, Conjugated	22	$9,430
Finasteride	343	$5,129
Estradiol	35	$3,074
Oxybutynin Chloride ErOxybutynin Chloride	100	$2,514
Tolterodine Tartrate	21	$2,501
NitrofurantoinNitrofurantoin Macrocrystal	37	$1,238
Tolterodine Tartrate ErTolterodine Tartrate	13	$866
Oxybutynin Chloride	58	$766
Solifenacin Succinate	19	$707
Ciprofloxacin Hcl	64	$337
Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim	115	$313
Doxazosin Mesylate	13	$250
Cephalexin	32	$147

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

Company	Paid to this provider	Part D cost of their drugs
PfizerPremarin	$90	$9,43022 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 46 urology providers in New Mexico.

Other urology in Farmington

Allen McCullochFarmington$2K
Stephen MannasFarmington$389
Christopher TaylorFarmington$49
Benjamin MontgomeryLovington$166K
Wayne KuangAlbuquerque$128K
Jordan ForemanAlbuquerque$60K
Emma BendanaLas Cruces$18K
Andrew GrollmanAlbuquerque$16K
Aaron GeswaldoAlbuquerque$11K
Jonathan NelsonAlbuquerque$6K

See the full list for New Mexico →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →